BridgeBio Pharma (BBIO) Assets Average (2019 - 2026)

BridgeBio Pharma has disclosed Assets Average across 8 years of filings, most recently posting $1.2 billion for Q1 2026.

• Assets Average for Q1 2026 came in at $1.2 billion, up 28.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 28.1% YoY), and the FY2025 annual result was $927.7 million, up 26.58% from the prior year.
• Assets Average came in at $1.2 billion for Q1 2026 at BridgeBio Pharma, up from $967.1 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $1.2 billion in Q1 2026 to a low of $564.7 million in Q2 2023.
• The 5-year median for Assets Average is $795.5 million (2022), against an average of $804.3 million.
• Across the five-year window, Assets Average plunged 32.59% in 2023 and soared 45.55% in 2024, its largest moves.
• BridgeBio Pharma's Assets Average stood at $675.9 million in 2022, then slipped by 11.13% to $600.7 million in 2023, then surged by 31.87% to $792.2 million in 2024, then rose by 22.09% to $967.1 million in 2025, then gained by 19.27% to $1.2 billion in 2026.
• The last three Assets Average figures came in at $1.2 billion (Q1 2026), $967.1 million (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.